Ramon A Torres

Address:

1400 Cricket Clb Cir APT 208, Orlando, FL 32828

VIN:

3A4FY48B47T527269

Make:

CHRYSLER

Model:

PT CRUISER

Year:

2007

US Patent:

6696063, Feb 24, 2004

Filed:

Dec 30, 1999

Appl. No.:

09/475989

Inventors:

Ramon A. Torres - New York NY

Assignee:

Applied Research Systems ARS Holding N.V. - Curacao

International Classification:

A61K 3900

US Classification:

4241981, 514 2, 530399

Abstract:

Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.

US Patent:

7144577, Dec 5, 2006

Filed:

Dec 3, 2003

Appl. No.:

10/725484

Inventors:

Ramon A. Torres - New York NY, US

Assignee:

Applied Research Systems ARS - Curacao

International Classification:

A61K 38/25
C07K 14/60

US Classification:

4241981, 514 2, 530399

Abstract:

Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.

US Patent:

20080004217, Jan 3, 2008

Filed:

Oct 25, 2006

Appl. No.:

11/552753

Inventors:

Ramon TORRES - New York NY, US

Assignee:

APPLIED RESEARCH SYSTEMS ARS - CURACAO

International Classification:

A61K 38/25
A61P 3/00
A61P 31/18

US Classification:

514012000

Abstract:

Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.